Tubulis, a Munich, Germany-based developer of protein-drug conjugates, closed a €10.7m Series A financing round.
The round was co-led by BioMedPartners and High-Tech Gründerfonds (HTGF) with participation from Seventure Partners, coparion, Bayern Kapital, and Occident, high net worth individuals and the founders.
The company intends to use the funds to accelerate the development of a new class of highly stable and efficient antibody-drug conjugates (ADCs).
Spun out in 2019 from the Leibniz Research Institute in Berlin (FMP) and the Ludwig Maximilians University (LMU) in Munich and led by Dominik Schumacher, CEO, Tubulis generates matched protein-drug conjugates by combining proprietary novel technologies with disease-specific biology.
The goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) and advance a variety of conjugates, unlimited by indication.
The company’s ADC technology portfolio consists of two proprietary technologies which are based on scientific discoveries made in the research groups of Prof. Christian Hackenberger (FMP), Prof. Heinrich Leonhardt (LMU) and Dr. Jonas Helma-Smets, who are all co-founders of the company. Jonas Helma-Smets also joined the company as CSO. The platforms accommodate the complexities of modern ADC design with regard to protein format, payload potency and payload hydrophobicity.